Reuters logo
BRIEF-Xenon Pharma says XEN801 did not meet endpoints in mid-stage study
March 24, 2017 / 11:10 AM / 6 months ago

BRIEF-Xenon Pharma says XEN801 did not meet endpoints in mid-stage study

March 24 (Reuters) - Xenon Pharmaceuticals Inc:

* Xenon Pharmaceuticals announces XEN801 did not meet efficacy endpoints in phase 2 clinical trial in patients with moderate to severe acne

* Xenon Pharmaceuticals announces XEN801 did not meet efficacy endpoints in phase 2 clinical trial in patients with moderate to severe acne

* Xenon Pharmaceuticals Inc - XEN801 did demonstrate a favorable safety and tolerability profile, with no drug-related serious adverse events

* Xenon Pharmaceuticals Inc - results also show that xen801 did not demonstrate statistical significance relative to key secondary efficacy endpoints Source text for Eikon: Further company coverage:

Our Standards:The Thomson Reuters Trust Principles.
0 : 0
  • narrow-browser-and-phone
  • medium-browser-and-portrait-tablet
  • landscape-tablet
  • medium-wide-browser
  • wide-browser-and-larger
  • medium-browser-and-landscape-tablet
  • medium-wide-browser-and-larger
  • above-phone
  • portrait-tablet-and-above
  • above-portrait-tablet
  • landscape-tablet-and-above
  • landscape-tablet-and-medium-wide-browser
  • portrait-tablet-and-below
  • landscape-tablet-and-below